Safety, PK and PD Study of ABX464 in Untreated HIV Patients
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is
intended to assess the safety, the tolerability, and pharmacokinetic parameters and to
evaluate the effect on viral load of repeated oral administrations of ABX464 in patients
infected by HIV, not previously treated for their HIV.
Two types of design are intended in this protocol: dosing every 3 days or dosing every day.
The goal is to determine the best dosing regimen to reduce viral load and minimize adverse
events.